Arcellx Inc. has announced that a late-breaking abstract detailing the unique high target-specificity of its novel D-Domain binder in anitocabtagene autoleucel (anito-cel) has been accepted for presentation at the 2026 Tandem Meetings, scheduled for February 4-7, 2026. The presentation will discuss preclinical study results showing that the D-Domain binder in anito-cel confers potent anti-tumor activity while minimizing tonic signaling and off-target reactivity. According to the abstract, anito-cel demonstrated no cases of delayed neurotoxicities or immune effector cell-associated enterocolitis to date, and the study found no tonic signaling or off-target activity with the D-Domain binder. Results will be presented during the late-breaking poster session on February 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260204502669) on February 04, 2026, and is solely responsible for the information contained therein.